Looking at the name of the German-based multinational corporation on the screen, Skater made himself believe it could happen. The art of the deal was in having something to sell to someone who wanted to believe you had something they wanted. "Saeder-Krupp is aggressive," he said, "and they own a few hundred other corps. If they were interested in NuGene before, they ought to really have a jones on once they find out about this new biotech."